91 related articles for article (PubMed ID: 32791525)
1. The Prognostic Significance of RB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas.
Richardson TE; Walker JM
J Neuropathol Exp Neurol; 2020 Sep; 79(9):1019-1023. PubMed ID: 32791525
[No Abstract] [Full Text] [Related]
2. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract][Full Text] [Related]
3. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.
Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE
Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875
[No Abstract] [Full Text] [Related]
4. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
Cimino PJ; Holland EC
Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961
[No Abstract] [Full Text] [Related]
5. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
6. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.
Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A
Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032
[No Abstract] [Full Text] [Related]
7. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
[TBL] [Abstract][Full Text] [Related]
8. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
9. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
[TBL] [Abstract][Full Text] [Related]
10. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
12. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
13. IDH-1 polymorphisms in pilocytic astrocytomas.
Prayson RA
Ann Diagn Pathol; 2019 Dec; 43():151411. PubMed ID: 31677487
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
15. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
[TBL] [Abstract][Full Text] [Related]
16. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
17. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
18. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
Tan Y; Zhang ST; Wei JW; Dong D; Wang XC; Yang GQ; Tian J; Zhang H
Eur Radiol; 2019 Jul; 29(7):3325-3337. PubMed ID: 30972543
[TBL] [Abstract][Full Text] [Related]
19. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
20. World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.
Hattori N; Hirose Y; Sasaki H; Nakae S; Hayashi S; Ohba S; Adachi K; Hayashi T; Nishiyama Y; Hasegawa M; Abe M
Cancer Sci; 2016 Aug; 107(8):1159-64. PubMed ID: 27196377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
